Method for constructing model for maintaining mouse totipotent embryo in vitro
By using PlaB to treat early mouse embryonic cells, combined with KSOM culture medium and DMSO dissolution, an all-purpose model closer to the natural state was established, which solved the problem of limited research on the all-purpose state, and a deep understanding of the all-purpose regulatory network and molecular mechanisms were obtained. , promotes the application of regenerative medicine and provides a tool for studying omnipotence balance.
Patent Information
- Application Number
- CN202411205539.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-11-26
AI Technical Summary
Research on the all-purpose state in the prior art is limited, there are differences between the all-purpose stem cell model and the all-purpose state of natural embryos. The all-purpose regulation mechanism is not fully understood, and it is difficult to maintain and understand the all-purpose state of early embryos in vitro.
Early mouse embryonic cells were treated with spliceosome inhibitor PlaB, combined with KSOM culture medium and DMSO dissolved, diluted to a concentration of 50 nM, and processed for a specific period of time to establish an all-around model closer to the natural state, and explore the all-around through sequencing technology Regulatory network and molecular mechanisms.
Establish an all-purpose model closer to the natural state, deeply understand the regulatory network and molecular mechanism of the all-purpose state, improve the understanding of the early embryonic all-purpose state, promote the application of regenerative medicine, and provide tools to study the balance of all-purpose. The problem of incomplete understanding of the all-round state maintenance and regulation mechanism is solved.
Smart Images

Figure CN119020267A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of early embryonic development and pluripotency research, and specifically relates to a method for constructing an in vitro mouse pluripotent embryo model, wherein the spliceosome inhibitor PlaB is used to treat early embryos to establish a pluripotent state maintenance model. Background Art
[0002] Totipotency refers to the ability of a single cell to generate a complete organism by itself. At the beginning of preimplantation development of mammalian embryos, a single embryonic blastomere has the potential to form all types of embryonic and extraembryonic cells, and this cell state is called the totipotent state. The first work to prove the totipotency of mammalian embryos was a paper published by Tarkowski in 1959. A single blastomere isolated from a two-cell embryo was able to develop into an entire adult mouse; however, mouse blastomeres at the four-cell or eight-cell stage gradually lost this ability. After these stages, embryonic cells begin to differentiate, first into the inner cell mass (ICM), forming fetal tissue, and then into the trophectoderm (TE), forming extraembryonic placental tissue. Therefore, most researchers believe that only mouse fertilized eggs and two-cell embryonic cells are fully totipotent. The totipotency of cells is crucial to the subsequent development of the embryo. In our understanding of the development of mammals, totipotency is a key concept and is essential for complete life individuals.
[0003] Early in development, the totipotent cells of the embryo have two different cell fates, namely the embryonic cell lineage (inner cell mass, ICM) and the extraembryonic cell lineage (trophectoderm). This transition occurs between the 4-cell stage and the morula stage in mice. Cells from the ICM can contribute to all types of embryonic lineages, but not to the cell types of the extraembryonic lineages. Therefore, ICM cells are pluripotent, not totipotent. Embryonic stem cells (ESCs) can be derived from ICM cells and maintain pluripotency in culture. Because ESCs can self-renew in culture, they have great potential in regenerative medicine, and the transcriptional and epigenetic networks that regulate their pluripotency have been widely studied. In contrast to pluripotency, our comprehensive study of the establishment and maintenance of the totipotent state is limited, in part because of the small number of totipotent cells present in preimplantation embryos. Currently, research on the regulatory mechanisms of totipotency is mainly focused on the identification and establishment of in vitro totipotent stem cell culture systems. In 2012, under serum / leukemia inhibitory factor (LIF) culture conditions, it was found that about 1%-2% of mouse embryonic stem cells (mESCs) exhibited the transcriptional characteristics of two-cell embryos, which were called two-cell-like embryonic stem cells (2CLCs). Since the discovery of 2CLCs, some molecular mechanisms regulating the totipotency state have been revealed using this totipotent-like stem cell model. However, there are still great differences between the totipotent-like stem cell model and the natural embryonic totipotency state. Given the current knowledge about totipotency, there is still a large gap in fully understanding the regulation and functional characteristics of the totipotency state. If totipotent embryos can be maintained in vitro, this will greatly advance our understanding of basic developmental processes and will provide great potential for regenerative medicine.
[0004] For the study of totipotency, experimental techniques applicable to early mammalian embryos are still limited. However, the innovative development of this in vitro mouse early embryo totipotency model for transient maintenance of totipotency makes it possible to have a deeper understanding of the mechanism of totipotency state and regulation. First, the use of the model of transient maintenance of totipotency in early embryos will help promote our understanding of the regulatory network of totipotency. It will reveal a new and important genetic factor for the process of cell fate conversion. Defining and studying cell state and fate determination from a new perspective may provide new breakthroughs and original discoveries for revealing the factors that affect cell fate determination, and help people have a deeper understanding of cell fate transformation. Secondly, using sequencing technology, we can accumulate knowledge to describe the specific characteristics of totipotent cells, and it can greatly help us to draw a map of embryonic development. Finally, totipotency represents the highest developmental potential of early embryogenesis, and therefore may contribute to the wide application of stem cells in reproduction, development, and tissue / organ regeneration. Obviously, further understanding of the molecular mechanism of totipotency regulation will further improve the efficiency of totipotency cell reprogramming and create more functional in vitro totipotency models for basic research and regenerative medicine.
[0005] The prior art closest to the present invention is to use the spliceosome inhibitor PlaB to treat early embryos to establish a model for the short-term maintenance of the omnipotent state, as well as the cultivation and research of omnipotent-like stem cells (2CLCs). At present, this model is also used to study splicing events during the activation of the zygotic genome. The results show that the splicing biological process is very critical in this process, but the PlaB impact stage is not further clarified, and there are still many aspects of the function of the early natural embryo model that need to be explored. The balanced state of omnipotence also shows a downward trend in this process. This exit trend is crucial for the normal development of early embryos, but there is no specific research and proof about the maintenance of the balance of omnipotence. This model provides a short-term natural early embryo development model for studying the balance of omnipotence, which can more realistically and accurately reflect the importance of omnipotence balance. This model treats embryos in the Pre-ZGA time period and models at precise time points. On the one hand, it can avoid the influence of confounding factors in the early embryo development process, and on the other hand, the results show that the maintenance and exit of the omnipotent state are crucial for embryo development. This model constructs a natural omnipotent embryo at a specific time, which is crucial for exploring early embryo development.
[0006] The existing technology mainly focuses on the construction of a totipotent stem cell model. PlaB is used to treat embryonic stem cells at different concentrations to obtain a two-cell-like cell line that has high totipotency and can develop into a blastocyst-like cell, simulating the outcome of early embryonic development ( Figure 1 ). However, the main problems and shortcomings of the prior art include limited comprehensive research on the establishment and maintenance of the totipotency state, differences between the totipotency-like stem cell model and the natural embryonic totipotency state, and incomplete understanding of the totipotency regulatory mechanism. The present invention aims to solve these problems by treating early embryos with the spliceosome inhibitor PlaB to establish a totipotency model that is closer to the natural state, and to deeply explore the totipotency regulatory network and molecular mechanism through sequencing technology, thereby promoting a deep understanding of the totipotency state and its application in regenerative medicine. Summary of the invention
[0007] In view of the technical problems existing in the prior art, such as the limited comprehensive study of the totipotency state, the difference between the totipotency-like stem cell model and the natural embryonic totipotency state, the incomplete understanding of the totipotency regulation mechanism, etc., the present invention uses the spliceosome inhibitor PlaB to treat early embryos to establish a totipotency model that is closer to the natural state, thereby promoting a deeper understanding of the totipotency state.
[0008] The first object of the present invention is to provide a method for constructing an in vitro mouse pluripotent embryo model, wherein the method comprises treating the two-cell stage of mouse early embryonic cells with PlaB.
[0009] Furthermore, the PlaB treatment is to add PlaB into mouse embryo culture medium.
[0010] Furthermore, the PlaB treatment is to dissolve PlaB in DMSO and then add it into mouse embryo culture medium.
[0011] Furthermore, the mouse embryo culture medium is KSOM culture medium.
[0012] In a specific embodiment, the PlaB drug is diluted to a working concentration of 50 nM and then added to mouse embryo culture medium.
[0013] The second object of the present invention is to provide a mouse natural pluripotent embryo model, wherein the mouse natural pluripotent embryo model is cultured using the aforementioned method.
[0014] The third object of the present invention is to provide the application of the aforementioned method or the aforementioned mouse natural pluripotent embryo model in the study of the regulatory mechanism of early embryo pluripotency.
[0015] The fourth object of the present invention is to provide the application of the aforementioned method or the aforementioned mouse natural omnipotent embryo model in the diagnosis strategy and / or treatment strategy of early embryonic development diseases.
[0016] The fifth object of the present invention is to provide the use of the aforementioned method or the aforementioned mouse natural omnipotent embryo model in screening, verifying, evaluating, assessing or studying the efficacy of drugs for preventing and / or treating early embryonic development diseases.
[0017] The present invention also provides the use of PlaB in constructing an in vitro embryo model for maintaining mouse pluripotency.
[0018] Furthermore, the PlaB treatment is to add PlaB into mouse embryo culture medium.
[0019] Furthermore, the PlaB treatment is to dissolve PlaB in DMSO and then add it into mouse embryo culture medium.
[0020] Furthermore, the mouse embryo culture medium is KSOM culture medium.
[0021] In a specific embodiment, the PlaB drug is diluted to a working concentration of 50 nM and then added to mouse embryo culture medium.
[0022] Pladienolide B (PlaB) described in the present invention is a natural antitumor analog of macrolides, which specifically binds to the splicing factor SF3B complex and has the function of inhibiting splicing. During the research process of the present invention, it was first discovered that the knockout of the SF3B subunit can activate the omnipotent marker gene, but it is not known whether PlaB is effective in activating the omnipotence of embryonic cells. Therefore, we want to know whether PlaB also has this effect in early embryos, which may be more helpful for us to understand the generation, maintenance and exit mechanism of the omnipotent state.
[0023] Studies have found that the addition of the spliceosome inhibitor PlaB to the culture medium can achieve the stable culture of totipotent embryonic stem cells, called totipotent blastomere-like cells (TBLCs). And TBLCs show similar epigenetic and transcriptomic characteristics to two-cell and four-cell embryos. Using this drug treatment may be more helpful for us to establish a model for the transient maintenance of the totipotent state of early embryos, and to understand the molecular mechanisms in the process of establishing the totipotent state directly through mouse embryos. So we used PlaB-treated early embryos as a model and combined sequencing technology to explore how the totipotent regulatory network is coordinated. We observed that the use of PlaB to treat zygotes caused embryonic development to be blocked at the two-cell stage. In order to determine the exact time and mechanism of action of PlaB, we treated it at different stages and found that the treatment at the main ZGA stage caused the most severe two-cell arrest phenotype. In the early embryonic development of mice, the two-cell and four-cell periods are considered to be the key time points for the transition from totipotency to pluripotency. We detected a series of changes in the transcriptome level after PlaB treatment in this process, the most critical of which was the effect on the transition from totipotency to pluripotency in early mouse embryos. Consistent with previous findings, we observed activation of totipotent genes, such as the totipotent factors Zscan4 and Dux. The activation of some transposon subfamilies, such as MERVL and MT2_Mm, was significantly enhanced, changing the lineage differentiation of early embryos. In addition, the activating factors involved in maintaining the totipotent transcriptional network in terms of transcriptional regulation, epigenetic regulation, cell cycle, DNA damage, etc. showed up-regulated expression (such as Dux, Obox family), and the repressor factor expression was down-regulated, resulting in a short-term maintenance of the totipotent state. It was confirmed that PlaB has a certain influence on early embryonic development and the maintenance of embryonic totipotency and pluripotency.
[0024] The beneficial effect of the technical solution of the present invention is
[0025] 1. Improve the understanding of the pluripotency state: By using the spliceosome inhibitor PlaB to treat early embryos, the present invention establishes a pluripotency model that is closer to the natural state. This helps to more deeply understand the regulatory network and molecular mechanism of the pluripotency state, thereby improving the understanding of the pluripotency state of early mammalian embryos.
[0026] 2. Revealing the regulatory mechanism of pluripotency: The present invention uses sequencing technology to study the transcriptome changes of embryos after PlaB treatment, revealing the regulatory network of the pluripotency state, and providing a new perspective for understanding the regulatory mechanism of pluripotency. This helps to solve the problem of incomplete understanding of the regulatory mechanism of pluripotency in the prior art.
[0027] 3. Promote the application of regenerative medicine: The present invention provides new tools and models for studying the molecular mechanism of pluripotency regulation, which helps to further improve the efficiency of pluripotent cell reprogramming and create more functional in vitro pluripotent models for regenerative medicine. This solves the problem of the difference between the pluripotent stem cell model and the natural embryonic pluripotency state in the prior art, and provides new possibilities for regenerative medicine.
[0028] 4. Provide new research tools: The present invention provides a short-term natural early embryonic development model for studying omnipotence balance, which can more realistically reflect the importance of omnipotence balance. This provides new tools and models for studying omnipotence balance, which helps to solve the problem of insufficient research on omnipotence balance maintenance in the prior art.
[0029] 5. Among them, we pay more attention to the explanation of pluripotency in basic research. By using the spliceosome inhibitor PlaB to treat early embryos, the present invention establishes a pluripotency model that is closer to the natural state. This helps to understand the regulatory network and molecular mechanism of the pluripotency state more deeply, thereby improving the understanding of the pluripotency state of early mammalian embryos. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 The data published in Science in 2014 were used for analysis. The results showed that the totipotent gene was highly expressed in the two-cell stage of the early embryo, indicating that the embryo entered the totipotent stage at this time, and then the expression of the totipotent gene was downregulated in the four-cell stage, indicating that the embryo exited the totipotent state.
[0031] Figure 2 A schematic diagram showing the duration and stage of PlaB treatment for early embryos.
[0032] Figure 3 The results of embryonic cell development after treating cells with PlaB for different time periods and in different time windows. The English names of the sample outcomes correspond to the Chinese names: Zygote, 2cell, 4cell, Morula, Blast, and Dead.
[0033] Figure 4 Representative stereomicroscope images of embryonic stages observed at indicated time points under different conditions (bar: 100 μm)
[0034] Figure 5 The line graph shows the development rate of embryos at different stages in the control group and the treatment group. Red: control group, n=112; blue: 50 nM PlaB treatment group, n=141
[0035] Figure 6 Immunofluorescence staining images of cytoskeleton at 36 hpf, 52 hpf, 84 hpf treated with PlaB and 84 hpf in the control group, red: cytoskeleton, blue: nucleus, (bar: 10 μm) (hpf: hours post-fertilization)
[0036] Figure 7 The heat map shows the published relative expression of omnipotent genes activated or silenced in various stages of mouse preimplantation embryos (Zhang B, Nature 2016) and in the treatment and control groups. Representative omnipotent genes are marked, and the red box marks the stage where the omnipotent genes are highly expressed.
[0037] Figure 8 Principal component analysis (PCA) reveals the transcriptome changes of the published mouse early preimplantation embryos at different stages and in the treated and control groups. The red dotted lines mark the dynamic changes of the transcriptome of the PlaB treated group and the control group at different times, and the axes are marked as the percentage of variance contained. DETAILED DESCRIPTION
[0038] The present invention is further explained below with reference to the examples, but the examples do not limit the present invention in any form.
[0039] The present invention uses the following reagent consumables:
[0040]
[0041]
[0042] Example 1
[0043] 1. In Vitro Fertilization (IVF)
[0044] 1. Preparation: Hormone ovulation
[0045] 1.1. Each female mouse (3 weeks old) was intraperitoneally injected with 5 IU (0.05 ml) of PMSG (Pregnant Mare Serum Gonadotropin), and 48 hours after the PMSG injection, 5 IU (0.05 ml) of hCG (Human Chorionic Gonadotropin) was injected. Fertilization was performed 14-16 hours after the hCG injection.
[0046] 1.2. Select 8-10 week old male mice and raise them individually to ensure the sperm motility of the male mice.
[0047] 1.3. Preparation of culture dishes:
[0048] (Energization dish): Use TYH to make two 150ul droplets, add 3ml mineral oil and cover them overnight for equilibrium.
[0049] (Fertilization dish): Use HTF to make a 150ul droplet, and make multiple 50ul small droplets next to it, and add 3ml mineral oil to cover and equilibrate overnight.
[0050] (Full culture dish): Use KSOM to make 9 50ul droplets and add 3ml mineral oil to cover and equilibrate overnight.
[0051] 2. Sperm Capacitation
[0052] On the day of egg retrieval, male mice were killed to obtain sperm from the tail of the epididymis for capacitation. Male mice aged 8-10 weeks were selected and killed by rapid cervical dislocation. The abdomen of the male mouse was wiped with a 70% alcohol cotton ball. After cutting the lower abdomen, the testicles were lifted up to reveal the vas deferens. The vas deferens was followed to the distal end with forceps, and the surrounding fat tissue was lifted and peeled off to find the tail of the epididymis. The tail of the epididymis was cut off and placed in a clean dish. It was immediately transferred to the embryo room for sperm retrieval. The sperm was gently squeezed with forceps to gather at the plump end of the tail of the epididymis. The tail of the epididymis was scratched with a syringe needle. The forceps were slightly squeezed to allow the sperm to overflow. The sperm was clamped and placed in the capacitation drop. One epididymal sperm was placed in one capacitation drop. The capacitation dish was placed in an incubator for incubation for 10 minutes. The capacitation dish was taken out and observed under a stereoscope to see if the sperm diffusion was normal. The normal capacitation dish was placed in an incubator for further incubation for 1 hour to 1 hour and 30 minutes.
[0053] 3. MII Oocyte Acquisition
[0054] One hour after sperm capacitation, the female mice were killed by cervical dislocation. The abdomen of the female mice was wiped with a cotton ball of 70% alcohol. The skin was pinched with ophthalmic forceps and a small incision was made on the skin with ophthalmic scissors. The skin was then pulled to the head with force to completely expose the abdomen. The peritoneum was then cut open with a second set of instruments to completely expose the internal organs. After the intestine was pulled to one side, the uterus and the connected ovaries on both sides could be seen in the abdominal cavity. The curled fallopian tubes were between the ovaries and the uterus. After cutting the lower abdomen, the fat was removed to see the uterus. The ophthalmic scissors were used to cut open between the ovaries and the fallopian tubes. The incision must be as close to the fallopian tube as possible. The forceps were moved to the fallopian tube to clamp the fallopian tube, and another cut was made between the fallopian tube and the uterus. The fallopian tube was placed in the fertilization dish. The dish with the fallopian tube was moved under the stereoscope, and two 1ml syringe needles were used to cut open the ampulla of the fallopian tube, release the COC, and pull the COC into the fertilization drop.
[0055] 4. Fertilization
[0056] Use a pipette to draw sperm (10-15ul) from the sperm capacitation dish and add it to the fertilization drop. The entire fertilization process should be completed within 5 minutes (from killing the mouse to fertilization and entering the box).
[0057] 5. Sperm washing
[0058] 5h30min--6h after fertilization, wash away the sperm in the HTF wash drop, and use a 100mm diameter pipette made from a 1.5mm capillary glass tube to move the fertilized egg from the fertilization drop into the KSOM culture dish drop to observe the formation of the pronucleus. The formation of the pronucleus and the expulsion of the second polar body are the signs of fertilization, and the fertilization rate is calculated.
[0059] 2. Modeling with PlaB reagent:
[0060] 1. Dilution of PlaB drug
[0061] The original drug was diluted to a stock concentration of 10 mM using DMSO, and then diluted to a working concentration of 50 nM using KMSO embryo culture medium.
[0062] 2. Cultivate at different times:
[0063] After washing the sperm in the previous step, we transferred the fertilized embryos to a culture dish containing 50nM KSOM culture droplets. The volume of each droplet was 50ul, and the embryo density in each droplet did not exceed 30 per droplet.
[0064] Then we use different periods of embryo culture. The specific culture is as follows:
[0065] Group 1: control, Group 2: PlaB (0-7hpf), Group 3: PlaB (10-24hpf), Group 4: PlaB (24-36hpf), Group 5: PlaB (36-48hpf), Group 6: PlaB (48-84hpf) (Note: hours post-fertilization) Figure 2 ).
[0066] 3. Observation results:
[0067] After culture, we observed the cell state of early embryonic cells and counted the cell development cycle and development ratio. At the same time, we used different cell development indicators for staining and evaluated related indicators such as cytoskeleton morphology and cell transcription activity.
[0068] PlaB was used to treat cells for different time periods and the development of embryonic cells was observed after cells were treated at different time windows. The results showed that the fourth group: PlaB (24-36hpf) early two-cell to late two-cell period (late-2C), after treating early embryonic cells in this major ZGA time window, the two-cell arrest phenotype was the most serious. At this time, the embryonic cells maintained a highly pluripotent state and could not exit the pluripotent state ( Figure 3 ).
[0069] PlaB at a concentration of 50 nM was used to culture mice from the zygote stage after fertilization, and it was found that the early embryos after culture were completely blocked at the two-cell stage and could not develop normally. Figure 4 ).
[0070] The whole process of embryonic cell development was observed and the development rate was calculated. The results showed that cells could not develop after PlaB treatment and a two-cell arrest occurred ( Figure 5 ).
[0071] When studying the effect of PlaB treatment on the embryonic cytoskeleton, we designed a series of immunofluorescence staining experiments, using the phalloidin F-actin as a marker to observe the morphology and structure of the cytoskeleton. We chose to observe at different time points (48 hours, 64 hours, and 96 hours) after PlaB treatment and compared with the cytoskeleton of normal embryos. The experimental results showed that with the extension of culture time, the cytoskeleton of PlaB-treated embryos showed obvious abnormal changes. At 48 hours of PlaB treatment, we observed that the embryonic cells began to collapse and shrink, the cytoskeleton became disordered, and the originally regularly arranged microfilament network became chaotic and lost its normal orderly structure. At 64 hours of PlaB treatment, the collapse and shrinkage of cells became more obvious, the abnormality of the cytoskeleton became more serious, and some cells even broke and dissolved, and the integrity of the cytoskeleton was seriously damaged. After 96 hours of PlaB treatment, the collapse and shrinkage of embryonic cells reached their peak, the abnormality of the cytoskeleton became more significant, the microfilament network of the cytoskeleton almost completely collapsed, the cell structure became loose and disordered, and the cell function was seriously affected. These experimental results show that PlaB treatment has a negative impact on the stability of the embryonic cytoskeleton, and this effect gradually intensifies with the extension of culture time. This abnormal change in the cytoskeleton may be one of the reasons for the abnormal function of embryonic cells and developmental arrest ( Figure 6 ).
[0072] 4. High-throughput sequencing:
[0073] In order to more comprehensively and intuitively evaluate the totipotency in embryos, we used the Smart-seq2 method to conduct experiments, evaluate the integrity of the model based on transcriptome data, and verify changes in the totipotency state of the model.
[0074] By deeply analyzing the cell transcriptome data, we found a remarkable phenomenon: although the overall transcription level of the cell showed a downward trend, most of the genes related to pluripotency were significantly activated, and these genes remained stable in the transcriptional activation state. This finding challenges our conventional understanding of cell state changes, that is, the activation state of these genes is unexpected in the context of overall transcriptional downregulation. By constructing a heat map to visualize these data, we clearly observed that after PlaB treatment, the genes related to pluripotency underwent significant activation. This activation is not only manifested at the transcriptional level, but also in the persistence of the activation state. This shows that despite the overall transcriptional downregulation, the activation of pluripotency genes is not a short-term phenomenon, but forms a state of sustained activation. Combining these observations, we can conclude that PlaB treatment can induce a special transcriptional pattern, in which although the overall transcriptional level decreases, the genes related to pluripotency show an abnormal activation state. The persistence of this activation state shows that PlaB may promote the stable expression of these genes through some mechanism, thereby maintaining a certain degree of "pluripotency" state at the transcriptional level ( Figure 7 ).
[0075] In order to gain a deeper understanding of the changes in cell states, we used a joint principal component analysis (PCA) method to compare the published RNA-seq data from the zygote to the blastocyst stage inner cell mass (ICM) with our transcriptome data. The PCA analysis results showed that 36 hours after PlaB treatment, the embryonic state was more primitive than the late two-cell state without PlaB, indicating that PlaB treatment may have caused the embryonic developmental state to regress to an earlier stage. Further observations revealed that 12 hours after PlaB release, that is, 48 hours, the cells of these embryos began to gradually develop backwards, but their state was more inclined to the two-cell state than the four-cell state without PlaB. This may be because PlaB treatment affects the subsequent development of the embryo, causing it to maintain a relatively primitive cell state for a certain period of time, and then after PlaB is released, these cells begin to resume backward development, but still have certain characteristics of the two-cell state.
[0076] In summary, our results show that PlaB treatment can affect the development process of the embryo, causing it to maintain a relatively primitive cell state for a certain period of time, and after PlaB is released, these cells begin to gradually resume their backward development. This discovery is of great significance for understanding the effects of PlaB on embryonic development and its regulatory mechanism ( Figure 8).
[0077] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for constructing an in vitro mouse pluripotent embryo model, characterized in that: The method is to use PlaB to treat two-cell stage of mouse early embryonic cells.
2. The method according to claim 1, characterized in that The PlaB treatment is to add PlaB into mouse embryo culture medium.
3. The method according to claim 2, characterized in that The PlaB treatment is performed by dissolving PlaB in DMSO and then adding it into mouse embryo culture medium.
4. The method according to claim 2, characterized in that: The mouse embryo culture medium is KSOM culture medium.
5. Application of PlaB in constructing an in vitro model for maintaining mouse pluripotency embryos.
6. A mouse natural pluripotent embryo model, characterized in that: The mouse natural omnipotent embryo model is obtained by culturing using the method described in any one of claims 1 to 4.
7. Use of the method according to any one of claims 1 to 4 or the mouse natural pluripotent embryo model according to claim 5 in the study of the regulatory mechanism of early embryo pluripotency.
8. Use of the method according to any one of claims 1 to 4 or the mouse natural omnipotent embryo model according to claim 5 in diagnostic strategies and / or therapeutic strategies for early embryonic development diseases.
9. Use of the method according to any one of claims 1 to 4 or the mouse natural omnipotent embryo model according to claim 5 in screening, verifying, evaluating, assessing or studying the efficacy of drugs for preventing and / or treating early embryonic development diseases.
